Stock comparison
Halozyme Therapeutics
SANUWAVE Health
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.41B
Sector
Healthcare
SNWV
SANUWAVE Health
Market cap
$137.85M
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | SNWV | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 38D | HALO |
| Benjamin Graham | 73B | 50C | HALO |
| Philip Fisher | 55C | 54C | HALO |
| Peter Lynch | 43D | 100A | SNWV |
| Joel Greenblatt | 30F | 57C | SNWV |
| Charlie Munger | 70B | 51C | HALO |
| Terry Smith | 74B | 44D | HALO |
Side-by-side metrics
| Metric | HALO | SNWV |
|---|---|---|
| Market cap | $8.41B | $137.85M |
| P/E (TTM) | 24.0x | 8.6x |
| EV/EBIT | 10.2x | 27.1x |
| ROIC (TTM) | 23.65% | 11.43% |
| Gross margin | 81.24% | 74.75% |
| Net margin | 23.13% | 36.21% |
| Revenue CAGR 5y | 33.23% | 35.65% |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 3.9x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Market cap$8.41Bvs $137.85M+98%
- Debt / Equity1.0xvs 3.9x+76%
- EV/EBIT10.2xvs 27.1x+62%
- ROIC (TTM)23.65%vs 11.43%+52%
SNWV leads on
- P/E (TTM)8.6xvs 24.0x+64%
- Net margin36.21%vs 23.13%+36%
- Revenue CAGR 5y35.65%vs 33.23%+7%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.